Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.
Feldman
Steven R
SR
Wake Forest University School of Medicine, Winston Salem, North Carolina 27157-1071, USA. sfeldman@wfubmc.edu
Kimball
Alexa Boer
AB
Krueger
Gerald G
GG
Woolley
J Michael
JM
Lalla
Deepa
D
Jahreis
Angelika
A
D000328:Adult; D004311:Double-Blind Method; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept